Columbia Gets $15M Grant to Develop Drugs for Rare Forms of ALS

Neil Shneider, MD, PhD, Claire Tow Associate Professor of Motor Neuron Disorders, the principal investigator on the grant and director of Columbia’s Eleanor and Lou Gehrig ALS Center, told Crain’s that drug development companies often don’t want to invest in therapies to treat such a small segment of people living with ALS. Therefore, the grant represents an opportunity to help an underserved portion of patients, he said. “Less than 1% of the 10 to 15% [of patients with genetic mutations] have these ultra-rare mutations,” he said. [read more]

Source: Crain's New York Business
Note: Accessing this article requires Crain's New York Business subscription.